We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $35.36 · 14 analysts
Stored first · Google News · Yahoo Finance (English)
Immunome stock up 32% in a month: Here's what you should know - MSN
Immunome stock up 32% in a month: Here's what you should know MSN
What This Immunome Sale Means a Day Before a Big FDA Milestone - The Motley Fool
What This Immunome Sale Means a Day Before a Big FDA Milestone The Motley Fool
What This Immunome Sale Means a Day Before a Big FDA Milestone
Why Immunome (IMNM) Is Up 11.7% After FDA Accepts Varegacestat NDA For Desmoid Tumors - Sahm
Why Immunome (IMNM) Is Up 11.7% After FDA Accepts Varegacestat NDA For Desmoid Tumors Sahm
Immunome Stock Up 32% in a Month: Here's What You Should Know - Yahoo Finance
Immunome Stock Up 32% in a Month: Here's What You Should Know Yahoo Finance
Immunome Stock Up 32% in a Month: Here's What You Should Know
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $-0.51 | — | — | $153.85K | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.52 | — | — | $2.93M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-3.72 | — | — | $6.3M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-2.97 | — | — | $3.39M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 29. | Truist Securities | — | Maintain | Buy → Buy | — | Truist Securities: Buy |
| 2026. 05. 28. | Barclays | — | Initiate coverage | — → Overweight | — | Barclays: Overweight |
| 2026. 05. 16. | Leerink Partners | — | Maintain | Outperform → Outperform | — | Leerink Partners: Outperform |
| 2026. 05. 13. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 03. 05. | Craig-Hallum | — | Maintain | Buy → Buy | — | Craig-Hallum: Buy |
| 2026. 03. 04. | Stephens & Co. | — | Maintain | Overweight → Overweight | — | Stephens & Co.: Overweight |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 7,034,952 | $151.11M | 0.25% | — | New position |